-
公开(公告)号:US07786287B2
公开(公告)日:2010-08-31
申请号:US10510912
申请日:2003-04-11
申请人: Osvaldo A. Flores , Jay Grobler , Edward M. Murray , Paul D. Zuck
发明人: Osvaldo A. Flores , Jay Grobler , Edward M. Murray , Paul D. Zuck
CPC分类号: G01N33/502 , C07K14/005 , C12N15/86 , C12N2730/10122 , C12N2840/203 , C12Q1/34 , C12Q1/6897 , C12Q1/707 , G01N33/5008 , G01N33/5067 , G01N33/5767 , G01N2333/18
摘要: The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3′ UTR based on the HCV-1a 3′ UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity.
摘要翻译: 本发明的特征在于使用β-内酰胺酶报道系统,HCV复制子增强细胞和/或含有基于HCV-1a 3'UTR的3'UTR的嵌合HCV复制子。 这些特征可以单独或一起使用,并且优选组合在一起以测量HCV复制子活性和化合物对这种活性的影响。
-
公开(公告)号:US20110014226A1
公开(公告)日:2011-01-20
申请号:US12921890
申请日:2009-03-17
申请人: Michael J. Caulfield , Michael D. Miller , Joseph G. Joyce , Paul D. Zuck , Krista L. Getty , Vadim Dudkin , Elizabeth A. Ottinger
发明人: Michael J. Caulfield , Michael D. Miller , Joseph G. Joyce , Paul D. Zuck , Krista L. Getty , Vadim Dudkin , Elizabeth A. Ottinger
IPC分类号: A61K39/385 , C40B30/04 , A61K39/21 , A61K39/29 , A61K39/095 , A61K39/00 , C07D401/12 , C07D211/60 , A61P37/04 , A61P31/18 , A61P31/14 , A61P31/04 , A61P37/02 , A61P29/00 , A61P3/10 , A61P25/00
CPC分类号: G01N33/564 , C07D211/60 , C07D211/62 , C07D401/12 , C12Q1/18 , G01N2333/162 , G01N2333/18 , G01N2333/22 , G01N2500/02
摘要: A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder.
摘要翻译: 用于鉴定可用作治疗剂和/或疫苗以预防,减轻或改善病原体感染或自身免疫性疾病的小分子的方法。 该方法可用于筛选小分子测试化合物以破坏感兴趣的特定抗原 - 抗体相互作用的能力。 在一个实施方案中,抗原是病原体衍生的抗原,当与抗原结合时,抗体降低或抑制病原体的毒力(例如,中和抗体,具有血清杀菌活性的抗体等)。 在另一个实施方案中,抗原是自身抗原(自身抗原),抗体是已知与病理状况(例如自身免疫性疾病)相关的自身抗体。 与抗原或抗体结合的化合物破坏结合可用作治疗剂以减少或抑制自身免疫性疾病。
-